Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pmidg LLC has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being processed by 2 distinct examiners. Unlike some smaller portfolios, this one is also split across 2 distinct art units. This suggests that the company's technical interests are diverse enough to fall under different administrative classifications within the USPTO's biotechnology division. The distribution across 2 distinct art units indicates a broader technical reach for the company's current research and development.
The busiest examiner for Pmidg LLC is GALSTER, SAMUEL LEONARD, who is responsible for 1 pending office action. Because there are 2 pending office actions in total, the workload is distributed equally among the 2 distinct examiners. This distribution across 2 distinct art units and 2 distinct examiners requires a broader management strategy than a single-unit portfolio. Practitioners should be prepared for different procedural nuances as they navigate these two separate channels at the patent office. The data shows that the company is not relying on a single point of contact for its current patenting goals.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| BAKSHI, PANCHAM | 1 | 76.8% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | BAKSHI, PANCHAM | 79d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | BAKSHI, PANCHAM | 79d overdue |
| 18265111 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | GALSTER, SAMUEL LEONARD | 75d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265111 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112DP | Non-Final OA | 75d | Pending | Jun 02, 2023 |
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | BAKSHI, PANCHAM | 1623 | §102§112 | Final Rejection | 79d overdue | Pending | Feb 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial